Search
forLearn
5 / 801 resultslearn Procyanidin B-2
learn phenoxyethanol
learn dehydroepiandrosterone
learn Ethynylestradiol
Research
5 / 130 results
research Ephrins Negatively Regulate Cell Proliferation in the Epidermis and Hair Follicle
Ephrins slow down skin and hair follicle cell growth.
research Multi-scale modeling for cell fate specification during regeneration and development
Signaling factors and gene-driven cell adhesion are crucial for wound healing and embryo development.
research Eph/ephrin signaling in epidermal differentiation and disease
Eph/ephrin signaling is important for skin cell behavior and could be targeted to treat skin diseases.
research Eph Receptors and Ephrins: Therapeutic Opportunities
Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.
research Different gene expression profile observed in dermal papilla cells related to androgenic alopecia by DNA macroarray analysis
Hair loss in balding individuals is linked to changes in specific hair growth-related genes.
Community Join
5 / 1000+ resultscommunity What makes breezula different than formula 82f?
Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.
community Beeezula off label (winlevi compounded)
User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community Cassiopea announces completion of recruitment of Phase II dose ranging trial of Breezula (CB-03-01) for androgenic alopecia
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
community Low level chronic allergies and hair loss
Hair loss can be influenced by chronic low-level allergies, and treatments like fexofenadine or topical cetirizine may help with regrowth. The user avoids finasteride, dutasteride, and minoxidil, and has tried Regenera Activa and PRF sessions.